HUTCHMED (China) Limited (HCM)

CIK 0001648257 · Healthcare · Drug Manufacturers

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
—
Statements
Consolidated Balance Sheets
—
Consolidated Balance Sheets (P)
—
Consolidated Statements of Operations
—
Consolidated Statements of Comprehensive Income
—
Consolidated Statements of Comprehensive Income/(loss)
—
Consolidated Statements of Changes In Shareholders' Equity
—
Consolidated Statements of Cash Flows
—
Notes
Accounts Payable
—
Accounts Receivable
—
Bank Borrowings
—
Cash and Cash Equivalents and Short-term Investments
—
Commitments and Contingencies
—
Cybersecurity Risk Management and Strategy Disclosure
—
Earnings Per Share
—
Earnings/(losses) Per Share
—
Fair Value Disclosures
—
Gain On Divestment of An Equity Investee
—
Government Grants
—
In-licensing Arrangement
—
Income Taxes
—
Insider Trading Policies and Procedures
—
Inventories
—
Investment In An Equity Investee
—
Investment In Equity Investees
—
Investment In Equity Security
—
Leases
—
Litigation
—
Note To Consolidated Statements of Cash Flows
—
Ordinary Shares
—
Organization and Nature of Business
—
Other Income/(expense)
—
Other Non-current Liabilities
—
Other Payables and Accruals
—
Other Payables, Accruals and Advance Receipts
—
Other Receivables, Prepayments and Deposits
—
Particulars of Principal Subsidiaries
—
Particulars of Principal Subsidiaries and Equity Investee
—
Pay Vs Performance Disclosure
—
Property, Plant and Equipment
—
Research and Development Expenses
—
Restricted Net Assets
—
Revenue
—
Segment Reporting
—
Share-based Compensation
—
Significant Transactions With Related Parties and Non-controlling Shareholders of Subsidiaries
—
Subsequent Events
—
Summary of Significant Accounting Policies
—